---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-22-000030"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2022-11-21T23:59:59+00:00"
generated_at: "2026-06-21T15:28:30.346876+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific adopts 2023 annual bonus and performance share programs

## Summary
- 2023 Annual Bonus Plan ties cash incentive to adjusted EPS, global sales (constant currency), ESG scorecard, and quality assessment.
- Bonus pool funding ranges from 0% to 150% of aggregate targets; CEO may adjust unit funding ±10%.
- 2023 rTSR PSP awards RSUs based on three-year TSR vs S&P 500 Healthcare Index (0-200% of target).
- 2023 Organic Net Sales PSP uses three-year organic sales growth vs plan (0-200% of target); replaces prior free cash flow program.
- All awards subject to recoupment policy for misconduct or financial restatement under Dodd-Frank clawback.

## SEC filing metadata
- accession: 0000885725-22-000030
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2022-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572522000030/0000885725-22-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572522000030/bsx-20221118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-22-000030
- JSON: https://secwatch.observer/filing/0000885725-22-000030.json
- Plain text: https://secwatch.observer/filing/0000885725-22-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.